Aarti Pharma -Financial Highlights: March 25

1) Pharmaceuticals company Aarti Pharmalabs announced Q4FY25 & FY25 results 2) Q4FY25 Financial Highlights: 3) Operational Revenue: Rs 5,638 million compared to Rs 5,058 million during Q4FY24, change 11.5%. EBITDA: Rs 1,456 million compared to Rs 1,175 million during Q4FY24, change 23.9%. EBITDA margin: 25.82% for Q4FY25. PBT: Rs 1,146 million compared to Rs 957 million during Q4FY24, change 19.7%. PAT: Rs 883 million compared to Rs 653 million during Q4FY24, change 35.2%. PAT margin: 15.66% for Q4FY25. 4) FY25 Financial Highlights: 5) Operational Revenue: Rs 21,151 million compared to Rs 18,526 million during FY24, change 14.2%. EBITDA: Rs 4,644 million compared to Rs 3,860 million during FY24, change 20.3%. EBITDA margin: 21.96% for FY25. PBT: Rs 3,607 million compared to Rs 3,005 million during FY24, change 20.0%. PAT: Rs 2,724 million compared to Rs 2,169 million during FY24, change 25.6%. PAT margin: 12.88% for FY25. Thank you, Technofunda24 This is all for information. This is not a buy/sell call.